SEC 13F Intelligence

Managers / Q3 2024 · view latest →

Duquesne Family Office LLC

CIK 0001536411 · Part of the Duquesne family · 40 WEST 57TH STREET, 25TH FLOOR, NEW YORK, NY, 10019 · (212) 830-6500

Reported Value
$3.0B
Q3 2024
Positions
75
Filings on Record
32
2019–present window
Filed
Nov 14, 2024
original filing

Summary

Duquesne Family Office LLC reported $3.0B in U.S.-listed holdings across 75 positions for Q3 2024.

Its largest position, NTRA, represents 15.3% of the portfolio.

Compared with Q2 2024, the fund opened 32 new positions and exited 22.

Portfolio Metrics

Turnover
+32.4%
vs prior filed quarter
Top-10 Concentration
+62.6%
share of reported value
Largest Position
+15.3%
Natera
New / Exited
32 / 22
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $1.7BQ4 ’18Q1 ’19: $3.4BQ2 ’19: $3.4BQ3 ’19: $2.6BQ4 ’19: $3.4BQ4 ’19Q1 ’20: $2.5BQ2 ’20: $3.3BQ3 ’20: $3.4BQ4 ’20: $3.7BQ4 ’20Q1 ’21: $4.5BQ2 ’21: $4.0BQ3 ’21: $3.1BQ4 ’21: $2.8BQ4 ’21Q1 ’22: $2.3BQ2 ’22: $1.4BQ3 ’22: $1.8BQ4 ’22: $2.0BQ4 ’22Q1 ’23: $2.3BQ2 ’23: $2.9BQ3 ’23: $2.8BQ4 ’23: $3.4BQ4 ’23Q1 ’24: $4.4BQ2 ’24: $2.9BQ3 ’24: $3.0BQ4 ’24: $3.7BQ4 ’24Q1 ’25: $3.1BQ2 ’25: $4.1BQ3 ’25: $4.1BQ4 ’25: $4.5BQ4 ’25Q1 ’26: $3.4Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 87.5%ADR: 4.9%ETP: 4.6%REIT: 2.5%Other: 0.5%
  • Common Stock · 87.5% · $2.6B
  • ADR · 4.9% · $145M
  • ETP · 4.6% · $135M
  • REIT · 2.5% · $74M
  • Other · 0.5% · $14M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
KRESpdr Ser TrNEW+2.05M2.05M+$116M$116M
AVGOBroadcom IncNEW+240.0K240.0K+$41M$41M
ASNDAscendis Pharma A/SNEW+265.0K265.0K+$40M$40M
NVTNvent Electric PlcNEW+451.1K451.1K+$32M$32M
TEVATeva Pharmaceutical Inds LtdNEW+1.43M1.43M+$26M$26M
United States Stl CorpNEW+663.1K663.1K+$23M$23M
CNMCore & Main IncNEW+475.2K475.2K+$21M$21M
CCitigroup IncNEW+327.4K327.4K+$20M$20M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2024

72 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1NTRANatera Inchistory →COM15.34%$453M3.57M
2CPNGCoupang Inchistory →CL A9.73%$287M11.70M
3COHRCoherent Corphistory →COM8.97%$265M2.98M
4WWDWoodward Inchistory →COM6.15%$181M1.06M
5STXSeagate Technology Hldngs Plhistory →ORD SHS6.09%$180M1.64M
6PMPhilip Morris Intl Inchistory →COM4.67%$138M1.13M
7KRESpdr Ser Trhistory →S&P REGL BKG3.94%$116M2.05M
8MELIMercadolibre Inchistory →COM3.34%$99M48.1K
9FCXFreeport-Mcmoran Inchistory →CL B2.33%$69M1.38M
10FLUTFlutter Entmt Plchistory →SHS2.09%$62M261.0K
11KMIKinder Morgan Inc Delhistory →COM1.95%$58M2.61M
12TECKTeck Resources Ltdhistory →CL B1.80%$53M1.02M
13VSTVistra Corphistory →COM1.57%$46M391.4K
14AVGOBroadcom Inchistory →COM1.40%$41M240.0K
15Discover Finl SvcsCOM1.35%$40M284.9K
16ASNDAscendis Pharma A/Shistory →SPONSORED ADR1.34%$40M265.0K
17MAAMid-Amer Apt Cmntys Inchistory →COM1.28%$38M238.7K
18CPTCamden Ppty Trhistory →SH BEN INT1.22%$36M290.9K
19DAKTDaktronics Inchistory →COM1.12%$33M2.57M
20WABWabtechistory →COM1.11%$33M179.7K
21NVTNvent Electric Plchistory →SHS1.07%$32M451.1K
22BMABanco Macro Sahistory →SPON ADR B0.91%$27M424.1K
23TEVATeva Pharmaceutical Inds Ltdhistory →SPONSORED ADS0.87%$26M1.43M
24BCSBarclays Plchistory →ADR0.83%$24M2.01M
25United States Stl CorpNEW COM0.79%$23M663.1K
26Springworks Therapeutics IncCOM0.77%$23M705.1K
27GTMZoominfo Technologies Inchistory →COMMON STOCK0.75%$22M2.14M
28CNMCore & Main Inchistory →CL A0.71%$21M475.2K
29CCitigroup Inchistory →COM NEW0.69%$20M327.4K
30VRNAVerona Pharma Plchistory →SPONSORED ADS0.67%$20M686.0K
31ARGTGlobal X Fdshistory →GB MSCI AR ETF0.63%$19M282.0K
32MSFTMicrosoft Corphistory →COM0.63%$19M43.1K
33ADBEAdobe Inchistory →COM0.61%$18M34.5K
34CRNXCrinetics Pharmaceuticals Inhistory →COM0.53%$16M309.0K
35CRHCrh Plchistory →ORD0.51%$15M162.5K
36GGALGrupo Financiero Galicia S.Ahistory →SPONSORED ADR0.51%$15M355.3K
37PANWPalo Alto Networks Inchistory →COM0.51%$15M43.7K
38WULFTerawulf Inchistory →COM0.47%$14M2.94M
39Flex LtdORD0.40%$12M348.9K
40CBChubb Limitedhistory →COM0.34%$10M34.8K
41ADSKAutodesk Inchistory →COM0.34%$10M36.4K
42MTBM & T Bk Corphistory →COM0.34%$10M56.2K
43TFCTruist Finl Corphistory →COM0.34%$10M233.5K
44TSMTaiwan Semiconductor Mfg Ltdhistory →SPONSORED ADS0.34%$10M57.4K
45USBUs Bancorp Delhistory →COM NEW0.34%$10M217.4K
46HBANHuntington Bancshares Inchistory →COM0.33%$10M671.2K
47CFGCitizens Finl Group Inchistory →COM0.33%$10M238.6K
48KEYKeycorphistory →COM0.33%$10M583.9K
49FHNFirst Horizon Corporationhistory →COM0.33%$10M619.7K
50ABCBAmeris Bancorphistory →COM0.33%$10M154.0K
51FCNCAFirst Ctzns Bancshares Inc Nhistory →CL A0.32%$10M5.2K
52YPFYpf Sociedad Anonimahistory →SPON ADR CL D0.31%$9M430.1K
53SPRYArs Pharmaceuticals Inchistory →COM0.26%$8M536.9K
54GEVGe Vernova Inchistory →COM0.25%$7M29.3K
55SLNSilence Therapeutics Plchistory →ADS0.24%$7M387.4K
56Arcellx IncCOMMON STOCK0.21%$6M74.1K
57TRPTc Energy Corphistory →COM0.19%$5M115.4K
58SBUXStarbucks Corphistory →COM0.17%$5M52.3K
59XPOXpo Inchistory →COM0.17%$5M46.5K
60PCVXVaxcyte Inchistory →COM0.17%$5M43.0K
61WDCWestern Digital Corp.history →COM0.17%$5M71.4K
62NAMSNewamsterdam Pharma Companyhistory →ORDINARY SHARES0.16%$5M287.5K
63RAREUltragenyx Pharmaceutical Inhistory →COM0.16%$5M85.4K
64BCYCBicycle Therapeutics Plchistory →SPONSORED ADS0.15%$4M190.2K
65ARMArm Holdings Plchistory →SPONSORED ADS0.10%$3M21.6K
66Ihs Holding LimitedORD SHS0.08%$2M770.3K
67TLSITrisalus Life Sciences Inchistory →COM0.07%$2M426.9K
68PLTRPalantir Technologies Inchistory →CL A0.05%$2M41.7K
69INSMInsmed Inchistory →COM PAR $.010.05%$1M20.0K
70NRIXNurix Therapeutics Inchistory →COM0.03%$993,00044.2K
71IVVDInvivyd Inchistory →COM0.02%$583,000571.4K
72JOBYJoby Aviation Inchistory →COMMON STOCK0.00%$113,00022.5K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$3.4B70May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$4.5B62Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$4.1B65Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$4.1B69Aug 15, 202513F-HRchanges · EDGAR ↗
Q1 2025$3.1B52May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$3.7B78Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$3.0B75Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$2.9B64Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$4.4B73May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$3.4B51Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$2.8B41Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2.9B53Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$2.3B48May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$2.0B58Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B65Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.4B43Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$2.3B51May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.8B49Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$3.1B49Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021REVEALED$4.0B52Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021REVEALED$4.5B64May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.7B56Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$3.4B61Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$3.3B72Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$2.5B46May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$3.4B62Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$2.6B43Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$3.4B61Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$3.4B61May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$1.7B31Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.